Unknown

Dataset Information

0

Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.


ABSTRACT: Brain metastases cause significant morbidity and mortality in patients with metastatic melanoma. Although adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) can achieve complete and durable remission of advanced cutaneous melanoma, the efficacy of this therapy for brain metastases is unclear. Records of patients with M1c melanoma treated with ACT using TIL, including patients with treated and untreated brain metastases, were analyzed. Treatment consisted of preparative chemotherapy, autologous TIL infusion, and high-dose interleukin-2. Treatment outcomes, sites of initial tumor progression, and overall survival were analyzed. Among 144 total patients, 15 patients with treated and 18 patients with untreated brain metastases were identified. Intracranial objective responses (OR) occurred in 28% patients with untreated brain metastases. The systemic OR rates for patients with M1c disease without identified brain disease, treated brain disease, and untreated brain disease, and were 49%, 33% and 33%, respectively, of which 59%, 20% and 16% were durable at last follow-up. The site of untreated brain disease was the most likely site of initial tumor progression (61%) in patients with untreated brain metastases. Overall, we found that ACT with TIL can eliminate small melanoma brain metastases. However, following TIL therapy these patients frequently progress in the brain at a site of untreated brain disease. Patients with treated or untreated brain disease are less likely to achieve durable systemic ORs following TIL therapy compared with M1c disease and no history of brain disease. Melanoma brain metastases likely require local therapy despite the systemic effect of ACT.

SUBMITTER: Mehta GU 

PROVIDER: S-EPMC6028054 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.

Mehta Gautam U GU   Malekzadeh Parisa P   Shelton Thomas T   White Donald E DE   Butman John A JA   Yang James C JC   Kammula Udai S US   Goff Stephanie L SL   Rosenberg Steven A SA   Sherry Richard M RM  

Journal of immunotherapy (Hagerstown, Md. : 1997) 20180601 5


Brain metastases cause significant morbidity and mortality in patients with metastatic melanoma. Although adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) can achieve complete and durable remission of advanced cutaneous melanoma, the efficacy of this therapy for brain metastases is unclear. Records of patients with M1c melanoma treated with ACT using TIL, including patients with treated and untreated brain metastases, were analyzed. Treatment consisted of preparative chemoth  ...[more]

Similar Datasets

| S-EPMC6171186 | biostudies-literature
| S-EPMC8857302 | biostudies-literature
| S-EPMC4981979 | biostudies-literature
| S-EPMC8144048 | biostudies-literature
| S-EPMC5490083 | biostudies-literature
| 2304475 | ecrin-mdr-crc
| S-EPMC3514199 | biostudies-literature
| S-EPMC10324027 | biostudies-literature
| S-EPMC5883986 | biostudies-literature
| S-EPMC6167746 | biostudies-literature